3 Questions You May Have Before Investing
1. Financial Health and Returns ?
a. Growth and Profitability:
"How is the company performing in terms of revenue growth and profitability ?"
KIC Ventures generates revenue, with NANISX experiencing approximately 40% profitable growth year-over-year since 2021.
b. Dividends:
"Does the company plan to distribute dividends to its investors ?"
KIC Ventures plans to distribute profits through dividends, potentially supplemented by mergers and acquisitions or partnership cash infusions.
c. Return on Investment:
"What is the anticipated timeline for investors to see a return on their investment ?"
KIC Ventures plans to distribute profits through dividends, potentially supplemented by mergers and acquisitions or partnership cash infusions.
d. Investment Appreciation:
"What are the projections for valuation increases, and how might they impact my potential returns ?"
A potential 12x increase in value is projected based on the current offering price and the estimated portfolio value upon achieving key technological milestones.
2. Investment Details ?
a. Minimum Investment Requirement:
"What is the minimum amount required to invest in the company ?"
The minimum investment amount is $25,000.
b. Investment Benefits:
"What benefits, financial or otherwise, will I receive from my investment ?"
Investors will receive Preferred Units in KICVentures, with more details provided in our Investment Documents.
c. Alternative Financing Options:
"If I am currently unable to invest cash, what alternative financing options are available ?"
Options such as margin loans against stocks, credit lines, or using retirement funds (IRA/401k) are available for those without immediate cash.
3. Risks and Compliance ?
a. Investment Security:
"How does the security of this investment compare to traditional retirement or savings investments ?"
Unlike retirement funds that are subject to stock market volatility, your investment in KICVentures is privately held and benefits from diversification across its portfolio.
b. Regulatory Approvals:
"What is the current status and expected timeline for obtaining FDA approval for AxioMed ?"
AxioMed has submitted all necessary modules and has successfully undergone an FDA clinical data audit. The manufacturing phase, which is the last step in the approval process, is expected to take 6-9 months and can be accelerated with capital.
c. Legal Standing:
"Is KIC Ventures currently facing any legal challenges with the Department of Justice (DOJ), and how could this affect the company ?"
KIC Ventures has resolved a previous DOJ civil investigation related to a whistleblower complaint, with the case settled and awaiting public release.
DISCLAIMER:
This presentation is subject to and conditioned upon the Investor’s (a) reviewing a Confidential Private Placement Memorandum; (b) executing a Subscription Agreement and Investor Questionnaire; (c) being qualified by the Issuer as an Accredited Investor under Regulation D. Investor shall pay no investment funds until all of the foregoing have occurred to the satisfaction of Company as the Issuer. This presentation does not take into account, nor does it provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. Company reserves the right to amend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to notify the recipient thereof.